Gail J Roboz1. 1. Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, New York 10065, USA. gar2001@med.cornell.edu
Abstract
PURPOSE OF REVIEW: The objectives of this review are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. RECENT FINDINGS: Most adults with AML die from their disease. The standard treatment paradigm for AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or allogeneic stem cell transplantation, depending on the patient's ability to tolerate intensive treatment and the likelihood of cure with chemotherapy alone. Although this approach has changed little in the last three decades, increased understanding of the pathogenesis of AML and improvements in molecular genomic technologies are leading to novel drug targets and the development of personalized, risk-adapted treatment strategies. Recent findings related to prognostically relevant and potentially 'druggable' molecular targets are reviewed. SUMMARY: At the present time, AML remains a devastating and mostly incurable disease, but the combination of optimized chemotherapeutics and molecularly targeted agents holds significant promise for the future.
PURPOSE OF REVIEW: The objectives of this review are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. RECENT FINDINGS: Most adults with AML die from their disease. The standard treatment paradigm for AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or allogeneic stem cell transplantation, depending on the patient's ability to tolerate intensive treatment and the likelihood of cure with chemotherapy alone. Although this approach has changed little in the last three decades, increased understanding of the pathogenesis of AML and improvements in molecular genomic technologies are leading to novel drug targets and the development of personalized, risk-adapted treatment strategies. Recent findings related to prognostically relevant and potentially 'druggable' molecular targets are reviewed. SUMMARY: At the present time, AML remains a devastating and mostly incurable disease, but the combination of optimized chemotherapeutics and molecularly targeted agents holds significant promise for the future.
Authors: Benet Pera; M Nieves Calvo-Vidal; Srikanth Ambati; Michel Jordi; Alissa Kahn; J Fernando Díaz; Weishuo Fang; Karl-Heinz Altmann; Leandro Cerchietti; Malcolm A S Moore Journal: Cancer Lett Date: 2015-08-12 Impact factor: 8.679
Authors: Jaime M Preussler; Christa L Meyer; Lih-Wen Mau; Navneet S Majhail; Ellen M Denzen; Kristen C Edsall; Stephanie H Farnia; Wael Saber; Linda J Burns; David J Vanness Journal: Biol Blood Marrow Transplant Date: 2017-03-02 Impact factor: 5.742
Authors: Nancy G Hedlund; Zeynep Isgor; Jack Zwanziger; Damiano Rondelli; Stephanie Y Crawford; Denise M Hynes; Lisa M Powell Journal: Health Serv Res Date: 2018-09-10 Impact factor: 3.402